Novartis
NEWS
It was yet another busy week for clinical trial announcements. Take a look.
CRISPR Therapeutics provided updated data from its ongoing Phase I CARBON trial of CTX110, its allogeneic “off-the-shelf” CAR-T therapy for CD19+ B-cell cancers.
With the planned departure from its 561,652-square-foot RTP campus, GSK will reduce its geographical footprint, but not its staff.
Once the deal is done, the company will be renamed MoonLake Immunotherapeutics and trade on the Nasdaq under the ticker symbol MLTX.
It was a busy week for clinical trial news. Here’s a look.
Biomolecular condensates could hold the key to unlocking a number of neurological diseases that have baffled researchers the longest.
There was still some carryover from the European Society of Medical Oncology Congress 2021, but there was plenty of other clinical trial news last week. Here’s a look.
The approval is based on its Phase III REACH3 trial, which evaluated Jakafi versus the best available therapy for treating chronic GVHD after allogeneic stem cell transplantation.
The startup’s initial focus will be on rare blindness conditions affecting pediatric patients.
JOBS
IN THE PRESS